Cargando…
Addressing the Continuum of Dysglycaemia and Vascular Complications in Prediabetes and Type 2 Diabetes: Need for Early and Intensive Treatment
The onset of type 2 diabetes increases the risk of vascular complications and death. We know now that that this risk begins long before the diabetes diagnosis. Prediabetes and type 2 diabetes are not separate entities in practice and exist within a continuum of dysglycaemia and vascular risk that in...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844108/ https://www.ncbi.nlm.nih.gov/pubmed/36760588 http://dx.doi.org/10.2147/DMSO.S396621 |
_version_ | 1784870548757544960 |
---|---|
author | Ghannam, Nadia Alahmed, Saleh Aldahash, Raed Aljohani, Naji Alshammary, Afaf Amir, Ashraf Kamal, Abdullah Khader, Said Salah, Mohammed Shalabi, Hani Abdallah, Ahmed Elboghdady, Ahmed |
author_facet | Ghannam, Nadia Alahmed, Saleh Aldahash, Raed Aljohani, Naji Alshammary, Afaf Amir, Ashraf Kamal, Abdullah Khader, Said Salah, Mohammed Shalabi, Hani Abdallah, Ahmed Elboghdady, Ahmed |
author_sort | Ghannam, Nadia |
collection | PubMed |
description | The onset of type 2 diabetes increases the risk of vascular complications and death. We know now that that this risk begins long before the diabetes diagnosis. Prediabetes and type 2 diabetes are not separate entities in practice and exist within a continuum of dysglycaemia and vascular risk that increases in severity over time. This excess risk requires early intervention with lifestyle therapy supported with pharmacologic antidiabetic therapy, intensified promptly where necessary throughout the duration of the diabetes continuum. Metformin is an evidence-based treatment for preventing prediabetes and improves cardiovascular outcomes in people with type 2 diabetes from diagnosis onwards. Newer agents (SGLT2 inhibitors and GLP-1 agonists) are appropriate for people presenting with type 2 diabetes and significant cardiovascular comorbidity. Additional therapies should be used without delay to achieve patients’ individualised HbA1c goals and to minimise cardiovascular risk. |
format | Online Article Text |
id | pubmed-9844108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-98441082023-02-08 Addressing the Continuum of Dysglycaemia and Vascular Complications in Prediabetes and Type 2 Diabetes: Need for Early and Intensive Treatment Ghannam, Nadia Alahmed, Saleh Aldahash, Raed Aljohani, Naji Alshammary, Afaf Amir, Ashraf Kamal, Abdullah Khader, Said Salah, Mohammed Shalabi, Hani Abdallah, Ahmed Elboghdady, Ahmed Diabetes Metab Syndr Obes Review The onset of type 2 diabetes increases the risk of vascular complications and death. We know now that that this risk begins long before the diabetes diagnosis. Prediabetes and type 2 diabetes are not separate entities in practice and exist within a continuum of dysglycaemia and vascular risk that increases in severity over time. This excess risk requires early intervention with lifestyle therapy supported with pharmacologic antidiabetic therapy, intensified promptly where necessary throughout the duration of the diabetes continuum. Metformin is an evidence-based treatment for preventing prediabetes and improves cardiovascular outcomes in people with type 2 diabetes from diagnosis onwards. Newer agents (SGLT2 inhibitors and GLP-1 agonists) are appropriate for people presenting with type 2 diabetes and significant cardiovascular comorbidity. Additional therapies should be used without delay to achieve patients’ individualised HbA1c goals and to minimise cardiovascular risk. Dove 2023-01-11 /pmc/articles/PMC9844108/ /pubmed/36760588 http://dx.doi.org/10.2147/DMSO.S396621 Text en © 2023 Ghannam et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Ghannam, Nadia Alahmed, Saleh Aldahash, Raed Aljohani, Naji Alshammary, Afaf Amir, Ashraf Kamal, Abdullah Khader, Said Salah, Mohammed Shalabi, Hani Abdallah, Ahmed Elboghdady, Ahmed Addressing the Continuum of Dysglycaemia and Vascular Complications in Prediabetes and Type 2 Diabetes: Need for Early and Intensive Treatment |
title | Addressing the Continuum of Dysglycaemia and Vascular Complications in Prediabetes and Type 2 Diabetes: Need for Early and Intensive Treatment |
title_full | Addressing the Continuum of Dysglycaemia and Vascular Complications in Prediabetes and Type 2 Diabetes: Need for Early and Intensive Treatment |
title_fullStr | Addressing the Continuum of Dysglycaemia and Vascular Complications in Prediabetes and Type 2 Diabetes: Need for Early and Intensive Treatment |
title_full_unstemmed | Addressing the Continuum of Dysglycaemia and Vascular Complications in Prediabetes and Type 2 Diabetes: Need for Early and Intensive Treatment |
title_short | Addressing the Continuum of Dysglycaemia and Vascular Complications in Prediabetes and Type 2 Diabetes: Need for Early and Intensive Treatment |
title_sort | addressing the continuum of dysglycaemia and vascular complications in prediabetes and type 2 diabetes: need for early and intensive treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844108/ https://www.ncbi.nlm.nih.gov/pubmed/36760588 http://dx.doi.org/10.2147/DMSO.S396621 |
work_keys_str_mv | AT ghannamnadia addressingthecontinuumofdysglycaemiaandvascularcomplicationsinprediabetesandtype2diabetesneedforearlyandintensivetreatment AT alahmedsaleh addressingthecontinuumofdysglycaemiaandvascularcomplicationsinprediabetesandtype2diabetesneedforearlyandintensivetreatment AT aldahashraed addressingthecontinuumofdysglycaemiaandvascularcomplicationsinprediabetesandtype2diabetesneedforearlyandintensivetreatment AT aljohaninaji addressingthecontinuumofdysglycaemiaandvascularcomplicationsinprediabetesandtype2diabetesneedforearlyandintensivetreatment AT alshammaryafaf addressingthecontinuumofdysglycaemiaandvascularcomplicationsinprediabetesandtype2diabetesneedforearlyandintensivetreatment AT amirashraf addressingthecontinuumofdysglycaemiaandvascularcomplicationsinprediabetesandtype2diabetesneedforearlyandintensivetreatment AT kamalabdullah addressingthecontinuumofdysglycaemiaandvascularcomplicationsinprediabetesandtype2diabetesneedforearlyandintensivetreatment AT khadersaid addressingthecontinuumofdysglycaemiaandvascularcomplicationsinprediabetesandtype2diabetesneedforearlyandintensivetreatment AT salahmohammed addressingthecontinuumofdysglycaemiaandvascularcomplicationsinprediabetesandtype2diabetesneedforearlyandintensivetreatment AT shalabihani addressingthecontinuumofdysglycaemiaandvascularcomplicationsinprediabetesandtype2diabetesneedforearlyandintensivetreatment AT abdallahahmed addressingthecontinuumofdysglycaemiaandvascularcomplicationsinprediabetesandtype2diabetesneedforearlyandintensivetreatment AT elboghdadyahmed addressingthecontinuumofdysglycaemiaandvascularcomplicationsinprediabetesandtype2diabetesneedforearlyandintensivetreatment |